Minaris Advanced Testing provides cGMP lot release and analytical support for in-vivo lentiviral CAR-T therapies. Our cGMP-compliant testing solutions are designed to support development, clinical manufacturing and ultimately, commercialization of in-vivo CAR-T. Backed by deep expertise in cell and gene therapy analytics, our team understands the unique complexities of lentiviral vector-based gene delivery and the critical quality attributes required to ensure safety, purity, potency, and regulatory compliance.
Download this flyer to see the full details of our comprehensive Drug Substance (DS) and Drug Product (DP) release testing panel, including identity, strength, potency, safety, and quality attribute assessments, as well as ICH-aligned stability support. Learn more about our ability to customize key assays—such as Replication-Competent Lentivirus (RCL), infectious titer, and potency—to address product-specific requirements and meet global regulatory expectations
